Close Menu

NEW YORK- A consortium led by Vancouver, Canada-based Canexia Health (formerly Contextual Genomics) has launched a C$2,590,500 (US$1.9 million) initiative that aims to improve access to testing and treatment options for Canadian cancer patients during the coronavirus pandemic.

The initiative, named Project ACTT (Access to Cancer Testing and Treatment), will deploy a liquid biopsy test that only requires a blood draw for cancer treatment selection, eliminating the need for most patients to travel to a hospital for biopsies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

In Science this week: chromatin accessibility of microglia during fetal development, and more.